Abstract
Aim To describe the risk of cardiovascular disease (CVD) in patients with classical Hodgkin lymphoma (cHL) undergoing contemporary treatment.
Methods Including all patients with cHL ≥18 years at diagnosis treated with doxorubicin-containing chemotherapy between 2000-2022. Patients were matched with comparators in a 1:5 ratio on birth year, sex, and Charlson Comorbidity Index at time of matching (score of 0 or ≥1). A composite of CVDs including coronary artery disease, heart failure, valvular stenoses, restrictive pericarditis, arrythmias, or any procedures related to these was the primary outcome. Follow-up started on date of cHL diagnosis (i.e., the matching date). The cause-specific cumulative incidence and 95% confidence intervals (CIs) were computed with all-cause death and lymphoma relapse as competing events using the Aalen-Johansen estimator.
Results A total of 1,905 patients with cHL and 9,525 comparators were included. Median age was 39 years (interquartile range, [IQR]: 27-56), 58% were males, most were treated with ABVD (83%), and the median cumulative doxorubicin dose was 250 mg/m2 (IQR: 200-300). Median follow-up was 10 years (IQR: 5.9-17.4). The cumulative incidences of CVD were 4.7% (95% CI: 3.6-5.7) for patients vs. 2.6% (95% CI: 2.3-2.9) for comparators at 5 years, 8.9% (95% CI: 7.2-10.5) vs. 5.5% (95% CI: 4.9-6.0) at 10 years, and 17.0% (95% CI: 14.1-19.9) vs. 8.2% (95% CI: 7.4-9.0) at 15 years.
Conclusions CVD remains a substantial late effect after contemporary treatment for cHL, suggesting that awareness of cardiac symptoms and a low threshold for referral to diagnostic examination are still important measures during survivorship.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Danish Cancer Association (grant number R327-A18892).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In Denmark, register-based studies performed for the sole purposes of statistics and scientific research do not require ethical approval nor informed consent. The study was registered in the Capital Region of Denmark (P-2023-320) in compliance with the Danish Data Protection Act and the General Data Protection Regulation
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability statement
The data underlying this article cannot be shared publicly due to ethical and privacy restrictions. The data will be shared on reasonable request to the corresponding author with permission of Statistics Denmark.
